Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $44.45 Consensus PT from Analysts

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been given an average rating of “Moderate Buy” by the twelve analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, nine have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $46.3636.

Several equities research analysts recently weighed in on the company. Barclays raised Celldex Therapeutics from an “underweight” rating to an “overweight” rating and increased their price target for the stock from $24.00 to $45.00 in a report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Monday. Wolfe Research raised Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 price target for the company in a report on Monday, March 23rd. Stifel Nicolaus reaffirmed a “buy” rating and set a $68.00 price target (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday, February 26th. Finally, The Goldman Sachs Group increased their price target on Celldex Therapeutics from $30.00 to $34.00 and gave the stock a “neutral” rating in a report on Monday, March 2nd.

Institutional Investors Weigh In On Celldex Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CLDX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Celldex Therapeutics by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock valued at $798,000 after acquiring an additional 680 shares during the period. Millennium Management LLC lifted its holdings in Celldex Therapeutics by 327.3% in the first quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company’s stock valued at $7,259,000 after acquiring an additional 306,330 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Celldex Therapeutics by 12.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company’s stock valued at $2,383,000 after acquiring an additional 14,979 shares during the period. Russell Investments Group Ltd. lifted its holdings in Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 501 shares during the period. Finally, Hsbc Holdings PLC acquired a new stake in Celldex Therapeutics in the second quarter valued at $347,000.

Celldex Therapeutics Trading Down 1.9%

CLDX stock opened at $33.55 on Friday. The business has a 50 day simple moving average of $30.10 and a 200-day simple moving average of $27.49. Celldex Therapeutics has a twelve month low of $17.85 and a twelve month high of $35.79. The company has a market capitalization of $2.23 billion, a P/E ratio of -8.62 and a beta of 1.19.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.22). The company had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $1.53 million. Research analysts predict that Celldex Therapeutics will post -4.87 EPS for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.